Comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea, and anorexia: a single-blind, randomized, crossover study

Add time:09/04/2019    Source:sciencedirect.com

Background: Ramosetron, a new specific 5-hydroxytryptamine3 (5HT3)-receptor antagonist, is 58 times more potent than granisetron, and its antiemetic effect lasts 10.7 times longer than that of granisetron in ferrets treated with cisplatin.Objective: This study was undertaken to compare the duration of efficacy and the safety profile of the selective 5HT3-receptor antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea, and anorexia.Methods: This single-blind, randomized, crossover, 3-site study compared a single intravenous (IV) infusion of ramosetron 0.3 mg with a single IV infusion of granisetron 3 mg 15 minutes before infusion of chemotherapy in male and female cancer patients aged 14 to 75 years. Patients were assessed for 24 hours after the start of chemotherapy infusion. Response criteria for emesis were as follows: completely effective, moderately effective, slightly effective, and not effective. Response criteria for nausea were as follows: moderately effective, slightly effective, and not effective. Anorexia was graded as mild, moderate, severe, or nonexistent. The severity of these events and their relationship to study treatment were assessed by the investigator.Results: A total of 111 patients were enrolled in the study. Data from 98 and from 110 patients were used to assess efficacy and safety, respectively. The ability of ramosetron to prevent emesis, nausea, and anorexia was similar to that of granisetron up to 6 hours after administration of chemotherapy, but from 18 to 24 hours after therapy ramosetron was significantly more effective than granisetron against nausea (P = 0.003) and anorexia (P = 0.04). The 2 drugs had a similar safety profile, and adverse events were generally mild and transient.Conclusions: The efficacy and safety profile of ramosetron are similar to those of granisetron, but ramosetron appears to have a longer duration of action than does granisetron.

We also recommend Trading Suppliers and Manufacturers of Ramosetron hydrochloride (cas 132907-72-3). Pls Click Website Link as below: cas 132907-72-3 suppliers

Prev:Prophylactic Antiemetic Efficacy of Granisetron or Ramosetron in Patients Undergoing Thyroidectomy
Next:Short communicationRapid and simultaneous analysis of protein and non-protein amino acids as N(O,S)-isobutoxycarbonyl methyl ester derivatives by capillary gas chromatography)